New drug cocktail targets Hard-to-Treat breast cancer mutation
NCT ID NCT04253561
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug, ipatasertib, added to two existing breast cancer medicines (trastuzumab and pertuzumab) in 17 people with advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation). The main goal was to find the safest dose of ipatasertib when used in this combination. Researchers also tracked side effects and early signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ipatasertib (an AKT inhibitor) combined with trastuzumab and pertuzumab
What this could lead to
If successful, this combination could offer a new treatment option for people with a specific genetic mutation in HER2-positive breast cancer that has spread.
What could go wrong
This is a very early, small Phase 1 study with only 17 participants, focused on finding the right dose and checking safety. It is not designed to prove the treatment works, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centro Integral Oncológico Clara Campal (CIOCC)
Madrid, Madrid, Spain
-
Comp. Hosp.Univ. Santiago (Chus)
Santiago de Compostela, La Coruña, Spain
-
Fundación Instituto Valenciano de Oncología
Valencia, Valencia, Spain
-
H.Univ. Arnau de Vilanova de Lleida
Lleida, Lleida, Spain
-
Hospital Universitario Doce de Octubre
Madrid, Madrid, Spain
-
Hospital Universitario Virgen del Rocio
Seville, Sevilla, Spain
-
Hospital Universitario del Vall d' Hebron
Barcelona, Barcelona, Spain
-
Hospital Virgen de Macarena
Seville, Sevilla, Spain
-
ICO Badalona
Badalona, Barcelona, Spain
-
MD Anderson
Madrid, Madrid, Spain